Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

Table 3 FEV₁ change from baseline and FF/VI vs placebo treatment difference following cessation of treatment

Day relative to last dose	Time point	Adjusted Mean FEV₁				Difference (FF/VI vs Placebo)	95% CI of the difference
Day relative to last dose	Time point	n	FF/VI 100/25 mcg	n	Placebo	Difference (FF/VI vs Placebo)	95% CI of the difference
0	AM	27	0.44	27	0.18	0.26	(0.16, 0.36)
	PM	27	0.44	27	0.07	0.38	(0.28, 0.48)
1	AM	27	0.38	27	0.02	0.36	(0.26, 0.46)
	PM	27	0.41	27	0.15	0.26	(0.16, 0.36)
2	AM	27	0.37	27	0.03	0.34	(0.24, 0.44)
	PM	27	0.41	27	0.16	0.24	(0.14, 0.34)
3	AM	27	0.31	27	0.05	0.26	(0.16, 0.36)
	PM	27	0.36	27	0.18	0.18	(0.08, 0.28)
4	AM	27	0.29	27	0.05	0.24	(0.14, 0.34)
	PM	27	0.34	26	0.18	0.17	(0.07, 0.27)
5	AM	27	0.24	26	0.17	0.07	(−0.03, 0.17)
7^a	AM	27	0.13	24	0.09	0.04	(−0.06, 0.14)
21^a	AM	27	0.06	27	0.03	0.03	(−0.07, 0.13)

Legend: Summary of repeated measures statistical analysis of change from baseline forced expiratory volume in one second (FEV₁), in litres, after cessation of repeat dose of treatment. Day 1 to Day 5 data was collected whilst subjects were in-patients. ^aDay 7 and Day 21 measurements were taken during outpatient visits

ISSN: 1465-993X